Relapsed Or Refractory Pediatric Low Grade Glioma Lgg Harboring A Braf Fusion Or Rearrangement — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for relapsed or refractory pediatric low grade glioma lgg harboring a braf fusion or rearrangement. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
4
Active US patents
39/100
Avg vulnerability
—
Annual revenue covered

Originators in Relapsed Or Refractory Pediatric Low Grade Glioma Lgg Harboring A Braf Fusion Or Rearrangement

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Day One Biopharms 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating relapsed or refractory pediatric low grade glioma lgg harboring a braf fusion or rearrangement. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
31
2
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Ojemda
TOVORAFENIB
 Day One Biopharms 4 39 — 2031-08-04

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10426782 Ojemda formulation 55 2035-06-23
10426782 Ojemda formulation 55 2035-06-23
8293752 Ojemda composition of matter 23 2031-08-04
8293752 Ojemda composition of matter 23 2031-08-04

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8293752 Ojemda composition of matter 23 2031-08-04
8293752 Ojemda composition of matter 23 2031-08-04
10426782 Ojemda formulation 55 2035-06-23
10426782 Ojemda formulation 55 2035-06-23

Related